A Predictive Model of Early Readmission for Patients with Heart Failure

Jian-Bo Hu 1,†, Zhong-Kai He 2,†, Li Cheng 3, Chong-Zhou Zheng 2, Bao-Zhen Wu 2, Yuan He 4,5,*, and Li Su 1,*

1 Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
2 Department of Structural Heart Disease, Cardiovascular Medicine Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, China
3 Department of Cardiology, Xinqiao Hospital of the Army Medical University, Chongqing 400037, China
4 Laboratory of Cardiovascular Diseases, Cardiovascular Medicine Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, China
5 Guangdong Provincial Engineering Technology Research Center for Molecular Diagnosis and Innovative Drugs Translation of Cardiopulmonary Vascular Diseases, University Joint Laboratory of Guangdong Province and Macao Region on Molecular Targets and Intervention of Cardiovascular Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, China

* Correspondence: heyuan@gdmu.edu.cn (Y.H.); suliqc@163.com (L.S.)
† These authors contributed equally to this work.

Abstract: Background: Readmission within 30 days of discharge for heart failure (HF) has become a challenging public health issue. Predicting the risk of 30-day readmission may assist clinicians in making individualized treatment plans for HF patients. Methods: A total of 2254 patients were enrolled in this study. The risk predictors associated with 30-day readmission were selected using the least absolute shrinkage and the selection operator regression model. The performance of the nomogram was evaluated using the receiver operating characteristic (ROC) curve, Hosmer–Lemeshow (HL) test, and decision curve analysis (DCA). Results: The 30-day all-cause readmission rate was 7.1%. Thirteen clinical parameters were identified as the risk predictors, including age, cystatin C, albumin, red cell distribution width coefficient variation, neutrophils, N-terminal pro-B-type natriuretic peptide, high-sensitivity cardiac troponin T, myoglobin, sex, dyslipidaemia, left ventricular ejection fraction, left ventricular end-diastolic dimension, and atrial fibrillation. The nomogram showed good discrimination, with an area under the ROC curve of 0.653 (95% confidence interval: 0.608–0.698) and good calibration results (HL test $p = 0.328$). The DCA showed that the nomogram would have good clinical utility. Conclusions: This predictive model based on clinical data makes it simple for clinicians to assess the 30-day HF readmission risk.

Keywords: predictive model; nomogram; heart failure; 30-day readmission

1. Introduction

Heart failure (HF) is a complex clinical syndrome that causes multiple related symptoms, such as dyspnea, fatigue, and peripheral or pulmonary edema, affecting the life quality of the patients [1]. While the medical equipment and techniques for treating HF have improved greatly in recent decades, hospitalization due to HF remains an increasingly serious problem worldwide [2]. The length of hospitalization of HF patients is often prolonged, and in many cases the patients will be readmitted to the hospital within a short time. Importantly, HF and its 30-day readmission rate have been a primary focus for reducing medical care costs [3]. Several prediction systems have been developed to identify high-risk patients for short-term readmission among the general medical population. However, they cannot be widely implemented for HF patients due to their poor consistency and practical performance [4–6]. While many indicators that are significantly associated with HF prognosis have been identified, few studies have used them to establish
a prognosis-prediction model. Indeed, in the Chinese population, the prediction of 30-day HF readmission only applies to elderly patients aged ≥65 years [7]. The emerging evidence suggests that the 30-day readmission rates for HF differ greatly in different hospitals and periods, potentially related to disease management [3,8]. Therefore, prediction models based on data from different countries and hospitals of different grades are not necessarily universally applicable. Consequently, there is an urgent need for novel predictive models for 30-day HF readmission in the Chinese hospitalized population.

Cardiovascular risk factors affect the HF all-cause death and readmission. Most HF patients suffer from one or more comorbidities, including metabolic syndromes, which are critical for disease progression and may exacerbate the HF treatment outcome. Non-cardiovascular comorbidities such as diabetes and chronic kidney disease are considered independent prognostic factors in HF patients, and their numbers can predict all-cause hospitalization and even short-term mortality [9,10]. Neurohumoral activation is also very important for HF diagnosis and prognosis, especially brain natriuretic peptide (BNP) and its precursor (NT-proBNP) [11]. In addition, blood cells, inflammatory and immune indicators, electrolytes, metabolites, and myocardial injury also contribute to HF prognosis [12–15]. In this study, we develop a predictive model of early readmission for HF patients based on clinical baseline data. To facilitate the operation of clinicians to predict the disease outcomes in advance, we screened out independent risk factors and developed a multi-factor predictive model that can effectively judge the early HF readmission.

2. Materials and Methods

2.1. Patients

We selected patients hospitalized for HF between January 2019 and December 2020 at the Affiliated Hospital of Guangdong Medical University (Zhanjiang, China). All the patients had to meet the following criteria: (1) HF diagnosed according to the 2018 guideline for HF diagnosis and treatment in China [16]; (2) aged ≥18 years; (3) received HF treatment during admission. Cases that died during the index admission or lost during follow-up were excluded. This study was approved by the ethics committee of the Affiliated Hospital of Guangdong Medical University, and consent was obtained from all participants. After excluding drug-related contraindications, all the selected patients received therapy for underlying diseases and triggers. In addition, the HF patients with preserved and mid-range left ventricular ejection fraction (LVEF) were given β-blockers to maintain heart rhythm at 50–70 beats/min, and those comorbid with sodium and water retention were given diuretics and aldosterone receptor antagonists (spironolactone). According to the individual patient situation, we used ivabradine, AECI/ARB, or ARNI to control blood pressure at 90–140 mmHg and used SGLT-2i to treat patients with type 2 diabetes. In addition to the above treatments, patients with reduced LVEF were treated with cardiotonic drugs such as digoxin and Qili Qiangxin capsules. The clinical baseline data and treatment methods were listed in Table 1.

Table 1. Baseline characteristics and 30-day readmission of the patients with HF.

| Overall | n = 2254 |
|---------|--------|
| Variables |         |
| Age, years | 71.54 ± 12.36 |
| Sex |         |
| Female, n (%) | 930 (41.26) |
| Male, n (%) | 1324 (58.74) |
| Smoking, n (%) | 269 (11.93) |
| Glu, µmol/L | 6.68 (5.32–8.92) |
| K, mmol/L | 3.98 ± 0.55 |
| Na, mmol/L | 138.90 ± 4.73 |
Table 1. Cont.

|                         | Overall                  |
|-------------------------|--------------------------|
| Scr, μmol/L             | 89.00 (72.00–114.00)     |
| SUA, μmol/L             | 403.00 (312.15–493.25)   |
| CysC, mg/L              | 0.97 (0.81–1.21)         |
| ALB, g/L                | 37.85 ± 4.51             |
| RDW-CV, %               | 14.41 ± 2.12             |
| HGB, g/L                | 123.10 ± 22.14           |
| NE, 10⁹ /L              | 8.48 (3.67–6.63)         |
| LY, 10⁹ /L              | 13.4 (9.96–1.82)         |
| NT-proBNP, pg/mL        | 1645.00 (686.78–4457.25) |
| hs-cTnT, ng/mL          | 0.03 (0.01–0.05)         |
| MYO, ng/mL              | 41.10 (28.20–65.43)      |
| LVEDD, mm               | 47.80 ± 8.86             |
| LVEF, %                 | 55.00 (45.00–60.00)      |

**Comorbidities**
- Diabetes, n (%) 826 (36.65)
- Dyslipidaemia, n (%) 582 (25.82)
- Hypertension, n (%) 1290 (57.23)
- Stable coronary heart disease 1599 (70.94)
- Acute coronary syndrome 375 (16.64)
- Atrial fibrillation 688 (30.52)
- Chronic kidney disease 238 (10.56)

**Treatment during hospitalization**
- β-blockers 1148 (50.93)
- Diuretics and aldosterone receptor antagonists 1303 (57.81)
- Ivabradine 118 (5.24)
- AECI/ARB 654 (29.02)
- ARNI 530 (23.51)
- SGLT-2i 191 (8.47)
- Digoxin 708 (31.41)
- Qili Qiangxin capsules 3 (0.13)

**Treatment after discharge**
- β-blockers 1072 (47.56)
- Diuretics and aldosterone receptor antagonists 1025 (45.47)
- Ivabradine 101 (4.48)
- AECI/ARB 516 (22.89)
- ARNI 495 (21.96)
- SGLT-2i 207 (9.18)
- Digoxin 400 (17.75)
- Qili Qiangxin capsules 5 (0.22)

**30-day readmission, n (%)**
- 160 (7.10)

Note: Glu, glucose; K, potassium; Na, sodium; Scr, serum creatinine; SUA, serum uric acid; CysC, cystatin C; ALB, albumin; RDW-CV, red distribution width coefficient variation; HGB, hemoglobin; NE, neutrophils; LY, lymphocytes; NT-proBNP, N-terminal pro-B-type natriuretic peptide; hs-cTnT, high-sensitivity cardiac troponin T; MYO, myoglobin; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction.

### 2.2. Clinical Data Collection

Clinical characteristics (age, sex, and smoking), laboratory findings (including glucose (Glu), potassium (K), sodium (Na), serum creatinine (Scr), serum uric acid (SUA), cystatin C (CysC), albumin (ALB), red cell distribution width (RDW) coefficient variation (CV), hemoglobin (HGB), neutrophils (NE), lymphocytes (LY), N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), myoglobin (MYO), left ventricular end-diastolic dimension (LVEDD), and LVEF), and comorbidities (diabetes, dyslipidaemia, hypertension, stable coronary heart disease, acute coronary syndrome, atrial fibrillation, and chronic kidney disease) of their first examinations were obtained from electronic medical records (Table 1). The primary outcome of this study was all-cause readmission within the first 30 days after discharge. The patients were followed up for...
30 days after discharge by telephone and their conditions were further confirmed in the hospital system.

2.3. Predictor Selection

Potential prognostic factors associated with the outcome were screened out using the least absolute shrinkage and selection operator (LASSO) method. The minimum criterion for 10-fold cross-validation in the LASSO model was used to determine the optimal penalty coefficient ($\lambda$), and the variable factor of a non-zero coefficient was defined as a risk predictor. Subsequently, a regression model was established using the binary logistic regression model.

2.4. Statistical Analysis

The continuous variables are reported as means ± standard deviations for parameters with normal distributions or medians and interquartile ranges for non-normal distributions. The categorical variables are reported as frequencies and percentages. Continuous variables were divided into categorical variables for analyses according to clinical routine cut-offs. The glmnet package in R was used to identify factors associated with 30-day readmission via LASSO regression. The selected predictors were incorporated into the binary logistic regression model to construct a predictive model. Then, a 30-day readmission risk-predictive nomogram model was constructed regarding discrimination and calibration. Finally, the calibration and discriminative abilities of the model were quantified using the Hosmer–Lemeshow (HL) test and receiver operating characteristic (ROC) curve, and the clinical applicability of the model was evaluated using a decision curve analysis (DCA).

All analyses were performed using the Stata v.15.0 (Stata Corporation, College Station, TX, USA) and R v.4.0.1 (R Foundation for Statistical Computing, Vienna, Austria). All results with $p < 0.05$ were considered statistically significant.

3. Results

3.1. Clinical Features of the Patients

The clinical baseline data for all 2254 patients included in this study are listed in Table 1. Their median age was 71.54 ± 12.36 years, and 1324 (58.74%) were male. Their 30-day all-cause readmission rate was 7.1%.

3.2. Risk Predictors for the Model

We screened the prediction variables from the baseline indicators and excluded variables with no clinical significance. The results of the LASSO analysis showed that several non-zero coefficients, including age, CysC, ALB, RDW-CV, NE, NT-proBNP, hs-cTnT, MYO, sex, dyslipidaemia, LVEDD, LVEF, and atrial fibrillation, were associated with 30-day readmission when the optimal $\lambda$ was 0.037 (Figure 1). Therefore, these factors were subsequently selected as predictors and included in the prediction model.

3.3. Predictive Nomogram for 30-Day Readmission

A nomogram was developed for prediction of the 30-day readmission risk (Figure 2). Then, the prediction model was internally validated via a 10-fold cross-validation analysis. The area under the ROC curve (AUC) was 0.653 (95% confidence interval: 0.608–0.698; Figure 3), indicating that the nomogram has good identification capability.

3.4. Performance of the Nomogram

The predictive accuracy and discriminative ability of the nomogram were assessed using a calibration curve. The HL test indicated good calibration ($p = 0.328$), and the calibration curves showed good agreement between the readmission risk and actual observation (Figure 4A). By comparing the net benefit of default strategies for treating all or no patients across different threshold probabilities, the DCA showed that the nomogram
could be clinically useful (Figure 4B). Altogether, the predictive nomogram is appropriate for clinically predicting the 30-day readmission risk of HF patients.

Figure 1. Predictor selection using the LASSO logistic regression model: (A) the penalty coefficient ($\lambda$) selection in the LASSO model used 10-fold cross-validation via minimum criteria; (B) LASSO coefficient distribution for 27 variables and non-zero coefficients selected in the LASSO coefficient profiles.

Figure 2. The 30-day readmission risk prediction nomogram. Key: CysC, cystatin C; ALB, albumin; RDW-CV, red distribution width coefficient variation; NE, neutrophils; NT-proBNP, N-terminal pro-B-type natriuretic peptide; hs-cTnT, high-sensitivity cardiac troponin T; MYO, myoglobin; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic dimension.
Figure 2. The 30-day readmission risk prediction nomogram. Key: CysC, cystatin C; ALB, albumin; RDW-CV, red distribution width coefficient variation; NE, neutrophils; NT-proBNP, N-terminal pro-B-type natriuretic peptide; hs-cTnT, high-sensitivity cardiac troponin T; MYO, myoglobin; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic dimension.

Figure 3. Receiver operating characteristic (ROC) curve of the nomogram [area under the curve (AUC)=0.653, 95% confidence interval (CI): 0.608–0.698].

3.4. Performance of the Nomogram

The predictive accuracy and discriminative ability of the nomogram were assessed using a calibration curve. The HL test indicated good calibration (p=0.328), and the calibration curves showed good agreement between the readmission risk and actual observation (Figure 4A). By comparing the net benefit of default strategies for treating all or no patients across different threshold probabilities, the DCA showed that the nomogram could be clinically useful (Figure 4B). Altogether, the predictive nomogram is appropriate for clinically predicting the 30-day readmission risk of HF patients.

4. Discussion

The readmission rate within 30 days is an important quality control indicator for HF patients. According to the survey, most of the 30-day readmission cases of HF occurred within two weeks after discharge. Therefore, accurately predicting the 30-day readmission risk of HF patients will help formulate appropriate diagnosis and treatment plans and disease management guidelines. In this study, we developed an easy-to-use nomogram based on readily available clinical variables, ensuring the wide applicability of our predictive model. Our findings showed that the all-cause 30-day readmission rate of the 2254 selected HF patients was 7.1%. The 30-day readmission prediction model developed based on independent predictors selected by multivariate analysis showed good internal consistency.
Overall, this prediction model can help to easily and quickly assessing a patient’s 30-day readmission risk, and may contribute to reducing the incidence of early readmission by adjusting the disease management plan.

A machine learning model was used to predict 30-day readmission in HF patients from seven major hospitals in the Boston Metro area and eastern Massachusetts [17]. However, it may be unsuitable for patients in other countries due to differences in disease management patterns and readmission rates. In addition, machine learning methods may be difficult for most clinicians as there are no equations used for calculating risk scores. Therefore, we used the LASSO method to develop a prediction model that will be easy for clinicians to evaluate the risk of 30-day HF readmission. Compared with an ordinary least squares estimation, LASSO can efficiently extract important variables and simplify the model when there are many candidate variables. In this study, the internal validation results showed that our nomogram based on the thirteen predictors selected by the LASSO method had good identification ability (Figure 1), although its AUC was slightly less than the machine learning model (Figure 3).

The clinical data used as the potential prognostic factors included leading baseline indicators, laboratory test indexes, and comorbidities, which may affect the HF outcome. The results of the LASSO regression analysis showed that age, CysC, ALB, RDW-CV, NE, NT-proBNP, hs-cTnT, MYO, sex, dyslipidaemia, LVEDD, LVEF, and atrial fibrillation were independent predictors of 30-day readmission (Figure 2). It has been shown that age and sex affect the prognosis of HF comorbid with diabetes [18,19]. Serum ALB has been associated with myocardial fibrosis [20], poor pulsatile aortic hemodynamics, and prognosis of HF with preserved ejection fraction [21]. Similarly, RDW and its changes during hospitalization are associated with 30-day mortality, the hospital stay length, and 30-day all-cause readmission [22]. Anemia, particularly persistent and new-onset anemia and milder temporary anemia, are suggested to be harmful to HF patients [23]. Inflammatory markers have been confirmed to be associated with adverse outcomes in HF patients [24]. NT-ProBNP secreted by the ventricle with increased wall stress is a prognostic HF biomarker [25]. In addition, hs-cTnT and serum ALB are two independent HF prognostic factors in the DCTA scoring system [26]. LVEDD ≤ 55 mm is an independent prognostic factor for LVEF recovery after clinical HF treatment [27]. Therefore, we used these significant risk factors to develop a predictive model for 30-day HF readmission.

Ibrahim et al. found that both the HOSPITAL Score and LACE index have poor specificity in predicting 30-day HF readmission [4]. In contrast to a scoring system, a risk prediction model is not just a simple mathematical combination of dependent and independent variables [28]. It must also possess a good discrimination ability and a good calibration degree. Some clinical indexes have been identified as the risk factors associated with adverse prognosis of HF [29]; however, using these factors to developed mathematical models may be more beneficial for predicting HF prognosis. Thus, we developed a 30-day readmission model using routine clinical indexes associated with HF prognosis. The AUC of the nomogram suggested that the 30-day readmission model had good discrimination ability (Figure 3). Moreover, the HL test and DCA indicated that this model also had a good degree of calibration and clinical usefulness (Figure 4).

This study is not unique in using this method to predict HF readmission. Both traditional and machine learning methods have been used in developing readmission models for HF patients from different grades of hospitals in different countries [8,17,28,30–33]. Nevertheless, machine learning methods may be difficult for most clinicians as there are no equations used for calculating risk scores. While the AUCs of the machine learning models are slightly higher than this prediction model, it may be unsuitable for patients in other countries due to differences in disease management patterns and readmission rates. Indeed, there are large differences in HF readmission rates among different hospitals. Our data were collected from a large-scale teaching hospital, where the 30-day readmission rate of HF patients appeared lower than the average reported by most studies. Therefore, we must establish a suitable predictive model to evaluate the 30-day HF readmission risk.
While the prediction model developed is relatively simple and useful, there remains room for improvement. In future studies, we will further develop novel biomarkers to predict HF prognosis.

5. Conclusions

In this study, we developed a novel nomogram for accurately predicting the risk of 30-day readmission for HF patients. The nomogram is easy to use and can assist clinicians in assessing the risk of 30-day HF readmission and making personalized treatment programs for HF patients. However, this study had several limitations. First, it was a retrospective observational study without external validation. In addition, we only focused on 30-day readmission without other endpoints such as 180-day readmission and death. Therefore, we plan to conduct a multicenter prospective cohort study on HF prognosis predictions.

Author Contributions: Methodology, Y.H. and L.S.; software, J.-B.H.; validation, Z.-K.H. and L.C.; formal analysis, J.-B.H. and L.C.; investigation, Z.-K.H. and C.-Z.Z.; data curation, C.-Z.Z. and B.-Z.W.; writing—original draft preparation, J.-B.H. and L.C.; writing—review and editing, Y.H. and Z.-K.H.; supervision, L.S.; project administration, Y.H. and L.S. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by grants from the Zhanjiang Science and Technology Development Special Funding Competitive Allocation Project (2021A05058).

Institutional Review Board Statement: The study was approved by the ethics committee of the Affiliated Hospital of Guangdong Medical University (approval No. P2021-108).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patients to publish this paper.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Baman, J.R.; Ahmad, F.S. Heart failure. JAMA 2020, 324, 1015. [CrossRef] [PubMed]
2. Rogers, C.; Bush, N. Heart failure: Pathophysiology, diagnosis, medical treatment guidelines, and nursing management. Nurs. Clin. N. Am. 2015, 50, 787–799. [CrossRef] [PubMed]
3. Goldgrab, D.; Balakumaran, K.; Kim, M.J.; Tabtabai, S.R. Updates in heart failure 30-day readmission prevention. Heart Fail. Rev. 2019, 24, 177–187. [CrossRef] [PubMed]
4. Ibrahim, A.M.; Koester, C.; Al-Akchar, M.; Tandan, N.; Regmi, M.; Bhattarai, M.; Al-Bast, B.; Kulkarni, A.; Robinson, R. HOSPITAL Score, LACE Index and LACE+ Index as predictors of 30-day readmission in patients with heart failure. BMJ. Evid. Based Med. 2020, 25, 166–167. [CrossRef] [PubMed]
5. Sudhakar, S.; Zhang, W.; Kuo, Y.F.; Alghrouz, M.; Barbajelata, A.; Sharma, G. Validation of the readmission risk score in heart failure patients at a tertiary hospital. J. Card. Fail. 2015, 21, 885–891. [CrossRef]
6. Huynh, Q.; Negishi, K.; De Pasquale, C.G.; Hare, J.L.; Leung, D.; Stanton, T.; Marwick, T.H. Validation of predictive score of 30-Day hospital readmission or death in patients with heart failure. Am. J. Cardiol. 2018, 121, 322–329. [CrossRef]
7. Lahewala, S.; Arora, S.; Tripathi, B.; Panaich, S.; Kumar, V.; Patel, N.; Savani, S.; Dave, M.; Varma, Y.; Badheka, A.; et al. Heart failure: Same-hospital vs. different-hospital readmission outcomes. Int. J. Cardiol. 2019, 278, 186–191. [CrossRef]
8. Yang, M.; Tao, L.; An, H.; Liu, G.; Tu, Q.; Zhang, H.; Qin, L.; Xiao, Z.; Wang, Y.; Fan, J.; et al. A novel nomogram to predict all-cause readmission in Chinese elderly patients with heart failure. ESC. Heart Fail. 2020, 7, 1015–1024. [CrossRef]
9. Paolillo, S.; Scardovi, A.B.; Campodónico, J. Role of comorbidities in heart failure prognosis Part I: Anaemia, iron deficiency, diabetes, atrial fibrillation. Eur. J. Prev. Cardiol. 2020, 27, 27–34. [CrossRef]
10. Tedeschi, A.; Agostoni, P.; Pezzuto, B.; Corra’, U.; Scrutinio, D.; La Gioia, R.; Raimondo, R.; Passantino, A.; Piepoli, M.F. Role of comorbidities in heart failure prognosis Part 2: Chronic kidney disease, elevated serum uric acid. Eur. J. Prev. Cardiol. 2020, 27, 35–45. [CrossRef]
11. Maries, L.; Manitiu, I. Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). Cardiovasc. J. Afr. 2013, 24, 286–289. [CrossRef]
12. Papadimitriou, L.; Kalogeropoulos, A.P. Inflammatory biomarkers and therapeutic targets in heart failure. Curr. Med. Chem. 2015, 22, 2716–2726. [CrossRef] [PubMed]
13. Costache, I.I.; Alexandrescu, D.M.; Cimpoeuş, D.; Petriș, O.R.; Petriș, A.O. Hyponatremia–risk factor in patients with chronic heart failure—Clinical, evolutive and therapeutic implications. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2014, 118, 315–319. [PubMed]
14. Borghi, C.; Palazzuoli, A.; Landolfo, M.; Cosentino, E. Hyperuricemia: A novel old disorder-relationship and potential mechanisms in heart failure. Heart Fail. Rev. 2020, 25, 43–51. [CrossRef] [PubMed]
